Novavax
NVAX · NASDAQ
$11.43+$0.61 (+5.64%)TodayMarket closed ·
Prev close $10.82
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 226.0% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.3933 | -$0.32 | +18.6% |
| Q1 FY26 | -$0.2349 | -$0.06 | +74.5% |
| Q4 FY25 | -$0.4967 | $0.11 | +122.1% |
| Q3 FY25 | -$1.21 | -$1.25 | −3.3% |
| Q2 FY25 | -$0.0852 | $0.62 | +827.7% |
| Q1 FY25 | $0.7201 | $2.93 | +306.9% |
| Q4 FY24 | -$0.5243 | -$0.83 | −58.3% |
| Q3 FY24 | -$0.8078 | -$0.76 | +5.9% |
Earnings calls
- Citigroup’s Biopharma Back to School Summit 2026
- 12th Annual Cantor Fitzgerald Global Healthcare Conference
- NVAX - Earnings call Q2 2026
- Jefferies Global Healthcare Conference 2026
- Bank of America Global Healthcare Conference 2026
- NVAX - Earnings call Q1 2026
- Leerink Global Healthcare Conference 2026
- TD Cowen 46th Annual Health Care Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.